The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
 
Isabel Arrillaga-Romany
Honoraria - Merck
Consulting or Advisory Role - Agios; Boehringer Ingelheim; FORMA Therapeutics; Insys Therapeutics; Karus Therapeutics
Research Funding - Astex Pharmaceuticals
 
Sylvia Christine Kurz
No Relationships to Disclose
 
Rohinton Tarapore
Employment - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Travel, Accommodations, Expenses - Oncoceutics
 
Ashley Sumrall
No Relationships to Disclose
 
Nicholas A. Butowski
Honoraria - DelMar Pharmaceuticals; Karyopharm Therapeutics; QED Therapeutics; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Bayer; Jazz Pharmaceuticals
Research Funding - Abbvie; Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Medicenna; Merck; Merrimack; Tocagen
 
Rebecca A. Harrison
No Relationships to Disclose
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics
 
Andrew S. Chi
Employment - Mirati Therapeutics; Neon Therapeutics
Consulting or Advisory Role - Cota Healthcare
Patents, Royalties, Other Intellectual Property - Fused Bicyclic Heterocycles as Therapeutic Agents (Inventor) Provisional Patent Application No. 62/742,041 filed on October 5, 2018
Travel, Accommodations, Expenses - Abbvie
 
Nicole A. Shonka
No Relationships to Disclose
 
Yoshie Umemura
No Relationships to Disclose
 
Yazmin Odia
No Relationships to Disclose
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Karyopharm Therapeutics; Tocagen
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - Xcision Medical Systems
 
Phioanh Leia Nghiemphu
Consulting or Advisory Role - Abbvie
Research Funding - Genentech/Roche; Novartis
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Guangrong Lu
Employment - Oncoceutics
 
Wolfgang Oster
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Joshua E. Allen
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Tracy Batchelor
Honoraria - UpToDate
Consulting or Advisory Role - Amgen; GenomiCare
Travel, Accommodations, Expenses - Genomicare
 
Andrew B. Lassman
Honoraria - Abbott Molecular; WebMD
Consulting or Advisory Role - Abbvie; Agios; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; QED Therapeutics; SapVax
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Keryx (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Oncoceutics
 
Patrick Y. Wen
Honoraria - Merck
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Decipher Biosciences; Genentech/Roche; Immunomic Therapeutics; Lilly; VBI Vaccines
Speakers' Bureau - Merck; Prime oncology
Research Funding - Abbvie; Agios; AstraZeneca; Genentech/Roche; Lilly
Travel, Accommodations, Expenses - Merck